Pricing Log in Create free account

Entrada Therapeutics, Inc. (TRDA) vs Upstream Bio, Inc. (UPB)

Entrada Therapeutics, Inc. and Upstream Bio, Inc. are both Biotechnology companies. Entrada Therapeutics, Inc. and Upstream Bio, Inc. are of similar size ($191.5M and $176.9M). Upstream Bio, Inc. grew revenue faster over the last twelve months: 16.0% against −93.5%. Entrada Therapeutics, Inc. has the higher net margin (−4,058.0% vs −4,955.7%) and the lower return on invested capital (−2,009.0% vs −1,100.9%). Across the 15 metrics below, Upstream Bio, Inc. leads on 8 and Entrada Therapeutics, Inc. on 7.

Valuation

Metric TRDA UPB Biotechnology median
P/E n/m n/m 10.60
P/S 52.10 55.81 9.40
P/B 1.04 0.65 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.50 0.66
EV/Sales 3.57 (26.93) 9.02
Earnings yield (78.53%) (89.78%) (32.88%)
Free cash flow yield (65.80%) (77.55%) (23.13%)

Profitability

Metric TRDA UPB Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (4,303.82%) (5,382.65%) 0.00%
Net margin (4,057.98%) (4,955.67%) 0.00%
Free cash flow margin (3,428.06%) (4,317.42%) 0.00%
Return on equity (59.88%) (46.05%) (51.96%)
Return on assets (47.48%) (44.61%) (46.06%)
Return on invested capital (2,008.96%) (1,100.93%) 0.00%

Growth

Metric TRDA UPB Biotechnology median
Revenue growth (TTM) (93.54%) 15.98% 6.76%
EPS growth (last fiscal year) (306.55%) 52.33% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric TRDA UPB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.85 27.99 4.97
Net debt to EBITDA 1.88 2.11 1.01

Dividend

Metric TRDA UPB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric TRDA UPB Biotechnology median
Market cap 191.45m 176.91m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack